Effectiveness comparison of patients with hepatitis C virus genotypes 1 or 4 therapies

IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Clinical Epidemiology and Global Health Pub Date : 2025-01-01 DOI:10.1016/j.cegh.2024.101880

Abdullah Althemery , Abdulrahman Alturaiki , Rawan Alanazi , Nawal Almotairi , Manal Aljohani , Khalefa Althiab , Abdullah Alfaifi

{"title":"Effectiveness comparison of patients with hepatitis C virus genotypes 1 or 4 therapies","authors":"Abdullah Althemery , Abdulrahman Alturaiki , Rawan Alanazi , Nawal Almotairi , Manal Aljohani , Khalefa Althiab , Abdullah Alfaifi","doi":"10.1016/j.cegh.2024.101880","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>HCV is a global threat and can lead to major complications. The aim of this study was to compare the rate of achieving SVR12 from sofosbuvir-based therapy versus paritaprevir-based therapy in patients with HCV genotypes 1 or 4 in the Kingdom of Saudi Arabia.</div></div><div><h3>Methods</h3><div>This study was a retrospective cohort design conducted between January 2016 and January 2019; Participants were classified into sofosbuvir-based therapy (SBT) or paritaprevir-based therapy (PBT). Also, HCV specific genotype was examined: genotype 1, genotype 4, or mixed genotypes. A series of descriptive statistics were designed to compare patient characteristics. Significant predictors of SVR12 were identified using a stepwise logistic regression analysis.</div></div><div><h3>Results</h3><div>A total of 387 patients (294 on SBT; 93 on PBT) were included. The two groups were similar in most predisposing factors. 25.58 % of the overall sample reported previous treatment failure. Five predictors were identified that influence the achievement SVR12: sex, HCV type, interruption of therapy, alanine transaminase level, and hemoglobin level.</div></div><div><h3>Conclusions</h3><div>Saudi patients with HCV infection have a higher incidence of having genotype 4. In addition, both treatment regimens were associated with high percentages of attaining SVR at 12 weeks. More research is needed, particularly regarding the role of mixed genotypes in treatment outcomes.</div></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":"31 ","pages":"Article 101880"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213398424003774","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background

HCV is a global threat and can lead to major complications. The aim of this study was to compare the rate of achieving SVR12 from sofosbuvir-based therapy versus paritaprevir-based therapy in patients with HCV genotypes 1 or 4 in the Kingdom of Saudi Arabia.

Methods

This study was a retrospective cohort design conducted between January 2016 and January 2019; Participants were classified into sofosbuvir-based therapy (SBT) or paritaprevir-based therapy (PBT). Also, HCV specific genotype was examined: genotype 1, genotype 4, or mixed genotypes. A series of descriptive statistics were designed to compare patient characteristics. Significant predictors of SVR12 were identified using a stepwise logistic regression analysis.

Results

A total of 387 patients (294 on SBT; 93 on PBT) were included. The two groups were similar in most predisposing factors. 25.58 % of the overall sample reported previous treatment failure. Five predictors were identified that influence the achievement SVR12: sex, HCV type, interruption of therapy, alanine transaminase level, and hemoglobin level.

Conclusions

Saudi patients with HCV infection have a higher incidence of having genotype 4. In addition, both treatment regimens were associated with high percentages of attaining SVR at 12 weeks. More research is needed, particularly regarding the role of mixed genotypes in treatment outcomes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.